Papillary type I vs type II renal cell carcinoma
Papillary renal cell carcinoma (pRCC) is the second most common [...]
AUA 2022: Should everyone have adjuvant therapy after surgery for high-risk kidney cancer?
The 2022 American Urological Association (AUA) Annual Meeting included a [...]
ASCO 2022: Sequencing of kidney cancer medicines
During the American Society of Clinical Oncology (ASCO) Annual Meeting [...]
High street pharmacies spot cancers in new NHS early diagnosis drive
NHS England announced a new system currently being trialled in [...]
Sequencing of treatments for advanced/metastatic kidney cancer
During the American Society of Clinical Oncology Annual Meeting earlier [...]
Three years follow-up data from the belzutifan study for pre-treated metastatic kidney cancer
Studies looking at the genes of people with kidney cancer [...]
Does the size of response to cabozantinib plus nivolumab affect clinical outcomes?
Ongoing results from the phase 3 CheckMate-9ER clinical trial with [...]
Can durvalumab or savolitinib alone or in combination with tremelimumab improve survival in patients with metastatic kidney cancer?
At the American Society of Clinical Oncology (ASCO) Annual Meeting [...]
Can adjuvant everolimus prevent recurrence following surgery?
At the American Society of Clinical Oncology (ASCO) Annual Meeting [...]
Is early treatment with adjuvant therapy healthy, cost effective and wise: the patient perspective?
Adjuvant therapy is medication that is given in addition to [...]
